208 related articles for article (PubMed ID: 37841254)
61. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
62. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
Péricart S; Tosolini M; Gravelle P; Rossi C; Traverse-Glehen A; Amara N; Franchet C; Martin E; Bezombes C; Laurent G; Brousset P; Fournié JJ; Laurent C
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30384489
[TBL] [Abstract][Full Text] [Related]
63. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
[TBL] [Abstract][Full Text] [Related]
64. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
65. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
66. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
67. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
68. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
69. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
Googe PB; Flores K; Jenkins F; Merritt B; Moschos SJ; Grilley-Olson JE
Am J Dermatopathol; 2021 Aug; 43(8):556-559. PubMed ID: 33156018
[TBL] [Abstract][Full Text] [Related]
70. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
[TBL] [Abstract][Full Text] [Related]
71. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
[TBL] [Abstract][Full Text] [Related]
72. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
[TBL] [Abstract][Full Text] [Related]
73. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
74. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
75. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS; Rothe M; Schnorfeil FM; Deiser K; Krupka C; Augsberger C; Schlüter M; Neitz J; Subklewe M
Front Immunol; 2018; 9():385. PubMed ID: 29535740
[TBL] [Abstract][Full Text] [Related]
76. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
77. CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.
Michot JM; Mouraud S; Adam J; Lazarovici J; Bigenwald C; Rigaud C; Tselikas L; Dartigues P; Danu A; Bigorgne A; Minard V; Ghez D; Marabelle A; Zitvogel L; Ribrag V
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771650
[No Abstract] [Full Text] [Related]
78. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract][Full Text] [Related]
79. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
80. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]